BridgeMD
New treatment option for Gastrointestinal Disease
Official title Application of Remimazolam Combined With Esketamine in Painless Gastroscopy and Colonoscopy in Elderly Patients
ClinicalTrials.gov ID: NCT07002801
What this study is testing
What is remimazolam-remifentanil?
remimazolam-remifentanil is an investigational medicine, being studied as a potential treatment for gastrointestinal disease.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The objective of this clinical trial is to assess the feasibility of the remimazolam combined with esketamine OFA (opioid-free anesthesia) protocol for painless gastroscopy and colonoscopy in elderly patients and to determine if it is non-inferior to the traditional OA (opioid-containing anesthesia) protocol. The main questions it aims to answer are: Is the remimazolam combined with esketamine protocol feasible for painless gastroscopy and colonoscopy in elderly patients?
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 65 and older
You may be able to join if
- Patients undergoing painless gastroenteroscopy in outpatient clinics;
- aged 65 years and above;
- American Society of Anesthesiologists (ASA) grades I - III.
You likely can't join if
- Patients with abnormal liver or kidney function;
- known respiratory or endocrine diseases;
- Patients with uncontrolled hypertension and NYHA classification Ⅲ-Ⅳ;
- Taking monoamine oxidase inhibitors, sedatives, analgesics, hypnotics, antipsychotics, antiemetics or antidepressants;
- Addiction to tobacco and alcohol;
- Patients allergic to the investigational drug;
See the full eligibility criteria
- Patients undergoing painless gastroenteroscopy in outpatient clinics;
- aged 65 years and above;
- American Society of Anesthesiologists (ASA) grades I - III.
- Patients with abnormal liver or kidney function;
- known respiratory or endocrine diseases;
- Patients with uncontrolled hypertension and NYHA classification Ⅲ-Ⅳ;
- Taking monoamine oxidase inhibitors, sedatives, analgesics, hypnotics, antipsychotics, antiemetics or antidepressants;
- Addiction to tobacco and alcohol;
- Patients allergic to the investigational drug;
- expected difficult airway;
- Body mass index (BMI) \>35kg/m\^2;
- Have participated in other clinical trials within the past three months;
- Patients with psychosocial illness or cognitive dysfunction and inability to cooperate or communicate.
The study team makes the final eligibility decision.
Where it's taking place
- Harbin, Heilongjiang, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Harbin, Heilongjiang, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.